Evidence map›Paper›PMID 39485351›Full record

Trial reportJAMA network open2024

Anemia Acuity Effect on Transfusion Strategies in Acute Myocardial Infarction: A Secondary Analysis of the MINT Trial.

François M Carrier, Howard A Cooper, Gerard T Portela, Marnie Bertolet, Gilles Lemesle, Micah Prochaska, Sarang Kim, John H Alexander, Ian Crozier, Gregory Ducrocq and 8 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02981407 (Myocardial Ischemia and Transfusion), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02981407 phase3completednot on this map

Myocardial Ischemia and Transfusion

TypeinterventionalSponsorRutgers, The State University of New JerseyRan2017 to 2023Enrolled3,506ConditionsMyocardial Infarction, AnemiaArmsRed Blood Cell Transfusion
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

François M CarrierDepartment of Anesthesiology and Department of Medicine, Critical Care Division, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Howard A CooperDepartment of Cardiology, Westchester Medical Center, Valhalla, New York.
Gerard T PortelaDepartment of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Marnie BertoletDepartment of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Gilles LemesleHeart and Lung Institute, University Hospital of Lille, CHU Lille, Lille, France.
Micah ProchaskaDepartment of Medicine, University of Chicago, Chicago, Illinois.
Sarang KimDepartment of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
John H AlexanderDuke Clinical Research Institute, Division of Cardiology, Duke University, Durham, North Carolina.
Ian CrozierDepartment of Cardiology, Christchurch Hospital, Christchurch, New Zealand.
Gregory DucrocqUniversité de Paris, Assistance Publique-Hôpitaux de Paris, French Alliance for Cardiovascular Trials, INSERM U1148, Paris, France.
Alexandre S QuadrosDepartment of Interventional Cardiology, Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, Brazil.
Akshay BagaiTerrence Donnelly Heart Center, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Marianna DracoulakisClinical Center Research-Hospital da Bahia, Dasa, Brazil.
Mina MadanDivision of Cardiology, Schulich Heart Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Maria M BrooksEpidemiology Data Center, Faculty in Epidemiology and Biostatistics, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.
Jeffrey L CarsonDepartment of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
Paul C HébertInnovation and Health Evaluation Hub, Centre de Recherche du CHUM, Montréal, Québec, Canada.
MINT Investigators

Funding

Myocardial Ischemia and Transfusion (MINT) - CCCU01HL133817 · NHLBI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI CARSON, JEFFREY LEE · 2016 to 2022
$17.1M
Myocardial Ischemia and Transfusion (MINT) - DCCU01HL132853 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BROOKS, MARIA MORI · 2016 to 2022
$4.1M
CIHRNHLBI NIH HHS U01 HL132853NHLBI NIH HHS U01 HL133817
6 · The paper itself

Abstract

Importance: In patients with acute myocardial infarction (MI), limited physiologic adaptation to acute anemia might lead to greater benefit from a liberal red blood cell (RBC) transfusion strategy. Data on such a possible benefit are lacking. Objectives: To compare acute anemia with chronic anemia and post-MI outcomes and estimate the differential effect of a restrictive RBC transfusion strategy compared with a liberal strategy on post-MI outcomes according to anemia acuity. Design, Setting, and Participants: A prespecified subgroup analysis of the Myocardial Ischemia and Transfusion (MINT) multicenter randomized clinical trial was conducted in 126 hospitals in 6 countries between April 26, 2017, and April 14, 2023, with 30-day follow-up and blinded adjudication of the primary outcome. The analysis included 3144 of 3504 MINT participants (89.7%) with acute MI, a hemoglobin (Hb) level less than 10 g/dL at randomization, and a first Hb measurement available on the day of or the day following hospital admission. Intervention: The MINT trial randomized participants to a restrictive (Hb <7-8 g/dL) or liberal (Hb <10 g/dL) RBC transfusion strategy. Acute anemia was defined as having a first Hb value greater than 13 g/dL (men) or 12 g/dL (women), or as having a decrease greater than or equal to 2 g/dL between the first Hb measurement and measurement at randomization. Other Hb levels were categorized as chronic anemia. Main Outcomes and Measures: The primary outcome was a composite of death or recurrent MI up to 30 days after randomization. Secondary outcomes were death, recurrent MI, cardiac death, heart failure, pulmonary complications, and major bleeding events. Intention-to-treat analysis was performed. Results: Among 3144 included participants (mean [SD] age, 72.3 [11.6] years; 1715 [54.5%] male; 1307 [41.6%] with type 1 MI), 1078 [34.3%]) had acute anemia. Acute anemia was associated with an increased risk of death or recurrent MI (adjusted risk ratio, 1.25; 95% CI, 1.05-1.48). The effect of a restrictive RBC transfusion strategy compared with a liberal strategy was similar for participants with either acute or chronic anemia for all outcomes. Conclusions and Relevance: In this secondary analysis of the MINT trial, acute anemia was associated with less favorable post-MI outcomes than chronic anemia but did not modify the effects of the randomized transfusion strategy. In patients with anemia and MI, the acuity of anemia should not influence the choice of transfusion trigger. Trial Registration: ClinicalTrials.gov Identifier: NCT02981407.

Indexed as

AnemiaErythrocyte TransfusionMyocardial InfarctionAgedFemaleHemoglobinsHumansMaleMiddle AgedHemoglobins

Identifiers

PMID39485351
PMCPMC11530937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.